U.S. stock market update: Tempus AI down 4.00%

U.S. Stock Market Midday Update Tempus AI fell 4.00%, with increased trading volume. Based on recent important news: On August 5, Portnoy Law Firm alerted investors about a securities fraud class action lawsuit against Tempus AI, leading to a drop in stock price. On August 4, Bernstein Liebhard LLP reminded investors of the upcoming lawsuit deadline, exacerbating market concerns. On August 4, MarketBeat reported that Tempus AI was not included in the recommended stock list, affecting investor confidence. Stocks with High Trading Volume in the Industry Thermo Fisher Scientific fell 3.83%, with increased trading volume. Based on recent key news: On August 6, Thermo Fisher Scientific was deemed less favorable than five other stocks by top analysts, leading to a decline in investor confidence and a drop in stock price. On August 6, market rumors suggested that Thermo Fisher Scientific might face operational disruptions in the coming months due to the impending retirement of its CFO, putting pressure on the stock price. On August 4, analysts only gave Thermo Fisher Scientific a "Moderate Buy" rating, failing to boost market confidence, resulting in a drop in stock price. Danaher fell 1.95%, with increased trading volume. Based on recent important news: On August 6, MarketBeat pointed out that Danaher was not included in the top analysts' recommended list of five stocks, despite being rated as a "Moderate Buy," leading to a decline in market confidence and a 1.95% drop in stock price. On August 5, analysts rated Danaher as "Hold," which was lower than the "Buy" ratings for its reinsurance peers, affecting market expectations for Danaher and its stock price. On August 4, Danaher was not included in the analysts' recommended list, weakening market confidence in its future performance and causing stock price fluctuations. Bio-Techne fell 9.72%, with a significant increase in trading volume. Based on recent important news: On August 6, Bio-Techne released its fourth-quarter financial report, showing a net loss of $17.677 million, a significant decline from last year's net profit of $40.6 million, leading to a 9.72% drop in stock price. On August 5, Bio-Techne announced the sale of Exosome Diagnostics to Mdxhealth for $5 million, and the market reacted poorly to its strategic adjustment. On August 6, analysts expressed concerns about Bio-Techne's profitability, particularly due to risks from U.S. pharmaceutical tariffs and tightening biotechnology funding. Stocks with High Market Capitalization in the Industry Agilent Technologies fell 1.51%, with increased trading volume. Based on recent key news: On August 5, Agilent Technologies' President and CEO Padraig McDonnell sold shares of the company, leading to a decline in market confidence and a drop in stock price On August 4th, Agilent Technologies announced the launch of the new Dako Omnis instrument series at the European Pathology Congress, with a lukewarm market response. On August 6th, MarketBeat reported that top analysts believe there are five stocks more worthy of investment than Agilent Technologies, further undermining investor confidence